No Data
No Data
Telo Genomics' Myeloma Test Accepted as Lab Developed Test by College of American Pathologists
Telo Genomics (TELO.V) said the College of American Pathologists (CAP) will add the company's test for smoldering multiple myeloma (SMM), TeloViewSMM, as a Laboratory Developed Test (LDT) on CAP's app
Telo Genomics Receives Accreditation From College of American Pathologists
Telo Genomics (TELO.V) a biotech company developing a telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, on Wednesday said the Accredit
Telo Genomics' MRD Clinical Trial Expands Into Multi-Center Trial; Shares up 9.5%
Telo Genomics (TELO.V) a biotech company developing a telomere technology platform with applications measuring genomic instability in oncology, reports that patient recruitment for its minimal residua